Savara jump­ing to the NYSE in re­verse merg­er with zom­bie biotech Mast

Af­ter rais­ing $20 mil­lion and lay­ing out plans for a Phase III piv­otal tri­al of a re­for­mu­lat­ed an­tibi­ot­ic, Savara is get­ting the new year un­der­way with a pub­lic list­ing, cour­tesy of a re­verse merg­er with the zom­bie biotech Mast Ther­a­peu­tics.

Mast had al­ready fall­en in­to pen­ny stock sta­tus last Sep­tem­ber when the com­pa­ny $MSTX was forced to con­cede that its Phase III study of a new drug for sick­le cell dis­ease had failed, leav­ing the San Diego-based biotech with few re­main­ing op­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.